title: BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts.
abstract: An increasing number of studies indicate that during development, endothelial and hematopoietic cells derive from common progenitors named hemangioblasts that have important roles in the pathogenesis. This is particularly true in chronic myeloid leukemia (CML). Here, we isolated fetal liver kinase-1-positive (Flk1(+)) cells from CML patients and found they expressed BCR/ABL-specific CML oncogene. We examined their biological characteristics as well as immunological functions and further detected the possible molecular mechanism involved in the leukemia genesis. We showed that CML patient-derived Flk1(+)CD31(-)CD34(-) mesenchymal stem cells (MSCs) had normal morphology, phenotype and karyotype but appeared impaired immuno-modulatory function. The capacity of Flk1(+)CD31(-)CD34(-) MSCs from CML patients to inhibit T lymphocyte activation and proliferation was impaired in vitro. CML patient-derived MSCs have dampening immuno-modulatory functions, suggesting that the dysregulation of hematopoiesis and immune response might originate from MSCs rather than hematopoietic stem cells (HSCs). These Ph(+) putative CML hemangioblast upregulated TGF-β1 and resultantly activated matrix metalloproteinase-9 (MMP-9) to enhance s-KitL and s-ICAM-1 secretion, which activated c-kit(+) HSCs from the quiescent state to the proliferative state. Further studies showed that phosphatidylinositol-3 kinase (PI3K)/Akt/nuclear factor (NF)-κB signaling pathway was involved in CML pathogenesis. Flk1(+)CD31(-)CD34(-) MSCs that express BCR/ABL leukemia oncogene are hemangioblasts and they have a critical role in the progression of CML through PI3K/Akt/NF-κB signaling pathway.
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: Q
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: S
authors.initials: S
authors.lastname: Fang
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: L
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: H
authors.initials: H
authors.lastname: Qi
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Xiangyang Central Hospital, Hubei University of Arts and Science, Xiangyang, China.
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: W
authors.initials: W
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D017209:Apoptosis / Q000502:physiology; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D055018:Hemangioblasts / Q000276:immunology* / Q000378:metabolism; D006801:Humans; D056747:Immunomodulation / Q000235:genetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000201:enzymology / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction; D055815:Young Adult
chemical_list: D019869:Phosphatidylinositol 3-Kinases; D016044:Fusion Proteins, bcr-abl
references.citation: Cancer Res. 2009 Jan 1;69(1):84-93
references.pmid: 19117990
references.citation: J Biol Chem. 1996 Jul 12;271(28):16567-72
references.pmid: 8663331
references.citation: Cell Cycle. 2009 Jan 1;8(1):18-22
references.pmid: 19106609
references.citation: J Cell Sci. 2008 Dec 15;121(Pt 24):4124-33
references.pmid: 19033389
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):626-33
references.pmid: 16428509
references.citation: J Biol Chem. 2004 Jan 9;279(2):1359-67
references.pmid: 14576166
references.citation: Blood. 2004 Oct 1;104(7):2163-71
references.pmid: 15213099
references.citation: J Biol Chem. 2000 Nov 24;275(47):36803-10
references.pmid: 10969078
references.citation: Leukemia. 2002 Jun;16(6):1160-6
references.pmid: 12040448
references.citation: Leuk Lymphoma. 2005 Jun;46(6):885-91
references.pmid: 16019534
references.citation: Haematologica. 2000 Feb;85(2):139-46
references.pmid: 10681720
references.citation: Int J Oncol. 2004 Nov;25(5):1375-82
references.pmid: 15492828
references.citation: Exp Hematol. 2003 Jul;31(7):650-8
references.pmid: 12842710
references.citation: Blood. 2002 Jun 1;99(11):4122-30
references.pmid: 12010816
references.citation: Nat Clin Pract Oncol. 2009 Feb;6(2):68-9
references.pmid: 19092801
references.citation: Blood. 2007 May 1;109(9):4016-9
references.pmid: 17213283
references.citation: J Leukoc Biol. 2005 Jul;78(1):259-65
references.pmid: 15800029
references.citation: Blood. 2001 Nov 1;98(9):2615-25
references.pmid: 11675329
references.citation: Eur J Haematol. 2003 Jun;70(6):373-8
references.pmid: 12756019
references.citation: J Biol Chem. 2004 Jan 16;279(3):1615-20
references.pmid: 14585846
references.citation: J Biol Chem. 2004 Sep 10;279(37):39042-50
references.pmid: 15247230
references.citation: Nature. 2005 Jul 7;436(7047):123-7
references.pmid: 16001073
references.citation: Cancer Lett. 2008 Aug 18;267(1):133-64
references.pmid: 18462866
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2666-75
references.pmid: 17121913
references.citation: Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):153-66
references.pmid: 12784994
references.citation: J Immunol. 2004 Jun 1;172(11):7015-23
references.pmid: 15153523
references.citation: Biol Blood Marrow Transplant. 2008 Sep;14(9 Suppl):8-15
references.pmid: 18721775
references.citation: Pharmacol Ther. 2001 Jul;91(1):1-34
references.pmid: 11707292
references.citation: Genes Dev. 2000 Jan 15;14(2):163-76
references.pmid: 10652271
references.citation: Cell Cycle. 2006 Dec;5(24):2862-6
references.pmid: 17172863
references.citation: Int J Oncol. 2003 Sep;23(3):681-91
references.pmid: 12888904
references.citation: Blood. 2006 Sep 1;108(5):1441-50
references.pmid: 16609063
references.citation: Mol Pharmacol. 2009 Mar;75(3):429-36
references.pmid: 19052170
references.citation: Hematology Am Soc Hematol Educ Program. 2008;:436-42
references.pmid: 19074122
references.citation: Leuk Lymphoma. 2002 Jun;43(6):1289-95
references.pmid: 12152998
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1828-38
references.pmid: 16551868
references.citation: Blood. 2005 Apr 1;105(7):2733-40
references.pmid: 15591120
references.citation: Nat Immunol. 2002 Jan;3(1):20-6
references.pmid: 11753406
references.citation: Blood. 2008 Jan 1;111(1):383-6
references.pmid: 17890452
references.citation: Clin Cancer Res. 1999 May;5(5):1115-24
references.pmid: 10353746
references.citation: Cell Cycle. 2008 Apr 15;7(8):1047-53
references.pmid: 18414048
references.citation: Blood. 2006 Nov 1;108(9):3143-51
references.pmid: 16840734
references.citation: Br J Haematol. 2004 Apr;125(2):128-40
references.pmid: 15059134
references.citation: Oncogene. 2002 Aug 8;21(34):5213-23
references.pmid: 12149643
references.citation: Curr Biol. 2000 Apr 20;10(8):439-48
references.pmid: 10801415
references.citation: Leuk Lymphoma. 2009 Jan;50(1):14-23
references.pmid: 19117213
references.citation: Biochem J. 2007 Aug 1;405(3):547-58
references.pmid: 17489740